% | $
Quotes you view appear here for quick access.

SIGA Technologies Inc. Message Board

hosaquavas 6 posts  |  Last Activity: 32 minutes ago Member since: Apr 30, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by coveman2000 Feb 12, 2015 1:01 PM
    hosaquavas hosaquavas Feb 12, 2015 9:06 PM Flag

    This Judgment, if the SC agrees or disagrees with Siga ends the relationship. PIP has no interest in Future Sigas good fortunes.

  • Reply to


    by gdc61411 Feb 14, 2015 7:10 AM
    hosaquavas hosaquavas Feb 16, 2015 8:12 PM Flag

    my attorney says that the interest stopped accruing on the day that Siga filed Chapter 11. Maybe someone here can confirm if that is correct.

  • getting closer to using some shares to end this lawsuit.

  • Pretty sure both SIGA and PIP filed some time ago, how long does the SP have to decide if they review again or reject? Anyone know if this decision has been made?

  • Reply to


    by tweendalines Apr 16, 2015 10:32 AM
    hosaquavas hosaquavas Apr 16, 2015 12:14 PM Flag

    tween, this is a $100 contract follow up that Barda said from the beginning that they were going to have two smalpox cures. Dont think Siga can protest this order. It also allows that they can expand to $435 Mll if they exercise all options. Probably not a good time for this to happen, guess Chimerix finally got their product to to point of acceptance Yahoo will not let me post the link but you can find it under Fedbzopps,gov solicitation #ntent-2015-1-SPXAV

  • Dr Rose once called compound St 669 his silver bullet?

    Another Rose failure? I am sure that he is a puppet for Perleman but he has been useless. This is an interesting 2014 publication regarding ST 669.

    Antimicrob Agents Chemother. 2014 Jul;58(7):3860-6. doi: 10.1128/AAC.02064-13. Epub 2014 Apr 28.
    The broad-spectrum antiviral compound ST-669 restricts chlamydial inclusion development and bacterial growth and localizes to host cell lipid droplets within treated cells.
    Sandoz KM1, Valiant WG1, Eriksen SG1, Hruby DE2, Allen RD 3rd2, Rockey DD3.
    Author information
    Novel broad-spectrum antimicrobials are a critical component of a strategy for combating antibiotic-resistant pathogens. In this study, we explored the activity of the broad-spectrum antiviral compound ST-669 for activity against different intracellular bacteria and began a characterization of its mechanism of antimicrobial action. ST-669 inhibits the growth of three different species of chlamydia and the intracellular bacterium Coxiella burnetii in Vero and HeLa cells but not in McCoy (murine) cells. The antichlamydial and anti-C. burnetii activity spectrum was consistent with those observed for tested viruses, suggesting a common mechanism of action. Cycloheximide treatment in the presence of ST-669 abrogated the inhibitory effect, demonstrating that eukaryotic protein synthesis is required for tested activity. Immunofluorescence microscopy demonstrated that different chlamydiae grow atypically in the presence of ST-669, in a manner that suggests the compound affects inclusion formation and organization. Microscopic analysis of cells treated with a fluorescent derivative of ST-669 demonstrated that the compound localized to host cell lipid droplets but not to other organelles or the host cytosol. These results demonstrate that ST-669 affects intracellular growth in a host-cell-dependent manner and interrupts proper development of chlamydial inclusions, possibly through a lipi droplet dependent process

2.050.0000(0.00%)Mar 19 4:00 PMEDT